You can buy or sell Zafgen and other stocks, options, ETFs, and crypto commission-free!
Zafgen, Inc. Common Stock, also called Zafgen, is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. Read More It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 9
Zafgen: 1Q Earnings Snapshot
BOSTON (AP) _ Zafgen Inc. (ZFGN) on Thursday reported a loss of $13.1 million in its first quarter. The Boston-based company said it had a loss of 35 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 40 cents per share. In the final minutes of trading on Thursday, the company's shares hit $2.61. A year ago, they were trading at $6.50. _____ This story was generated by Automated Insights (http://...
Simply Wall StApr 26
Did Changing Sentiment Drive Zafgen’s (NASDAQ:ZFGN) Share Price Down A Worrying 62%?
Even the best stock pickers will make plenty of bad investments. And there’s no doubt that Zafgen, Inc. (NASDAQ:ZFGN) stock has had a really bad year. In that relatively short period, the share price has plunged 62%. To make matters worse, the returns over three years have also been really disappointing (the share price is 60% lower than three years ago). Furthermore, it’s down 43% in about a quarter. That’s not much fun for holders. Check out our latest analysis for Zafgen Zafgen hasn’t yet reported any ...
Expected Aug 6, After Hours